SPS
MLTX icon

Susquehanna Portfolio Strategies’s MoonLake Immunotherapeutics MLTX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.73M Hold
253,974
– – 0.07% 314
2025
Q4 		$3.35M Buy
+253,974
New +$3M 0.05% 382

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna Portfolio Strategies's MLTX Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its MoonLake Immunotherapeutics (MLTX) position steady in Q1 2026 at 253,974 shares worth $4.73M. The position accounts for 0.07% of the portfolio, ranked #314.

Susquehanna Portfolio Strategies first reported a position in MLTX in Q4 2025 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Susquehanna Portfolio Strategies held 253,974 shares of MoonLake Immunotherapeutics worth $4.73M as of Q1 2026.
  • Susquehanna Portfolio Strategies left its MoonLake Immunotherapeutics share count unchanged in Q1 2026.
  • MoonLake Immunotherapeutics made up 0.07% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #314 holding.
  • Susquehanna Portfolio Strategies first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.